Controlled substance analgesic benzomorphans

TrkA-IN-1 is a potent and selective Tropomyosin-related kinase A (TrkA) inhibitor with an IC 50 of 99 nM in a cell-based assay. TrkA-IN-1 has analgesic activityForm:SolidIC50&amp: Target:TrkA 99 nM (IC 50 ) TrkB 81 μM (IC 50 ) TrkC 25 μM (IC 50 ).

TrkA-IN-1 is a potent and selective Tropomyosin-related kinase A (TrkA) inhibitor with an IC 50 of 99 nM in a cell-based assay. TrkA-IN-1 has analgesic activityForm:SolidIC50&amp: Target:TrkA 99 nM (IC 50 ) TrkB 81 μM (IC 50 ) TrkC 25 μM (IC 50 ).

TrkA-IN-3 is a potent, subselective and allosteric TrkA inhibitor, with an IC 50 of 22.4 nM. TrkA-IN-3 shows more than 8000-fold selectivity for TrkA over TrkB and TrkC . TrkA-IN-3 can be used for the research of pain.Appearance:SolidIC50&amp:

ApplicationtrYPhos™ is an ylide-functionalized phosphine ligand with demonstrated uses in Pd-catalyzed cross coupling reactions, including the arylation of ketones and arylation of amines.

ApplicationtrYPhos™ is an ylide-functionalized phosphine ligand with demonstrated uses in Pd-catalyzed cross coupling reactions, including the arylation of ketones and arylation of amines.

Application Buchwald palladacycle precatalyst with new biaryl(dialkyl)phosphine ligand, VPhos, has an improved activity profile for the reductive coupling of non-aromatic heterocyclic alkyl bromides. Its combined use with a surfactant system of

YHO-13351 free base is the prodrug of YHO-13177, which is a potent and specific inhibitor of BCRP .

Biochem/physiol Actions ZCZ011 is a brain-penetrant, cannabinoid receptor CB1-selective positive allosteric modulator (PAM) that enhances orthosteric agonist CP55,940, while reduces orthosteric inverse agonist SR141716A, CB1 binding. ZCZ011

Biochem/physiol Actions ZCZ011 is a brain-penetrant, cannabinoid receptor CB1-selective positive allosteric modulator (PAM) that enhances orthosteric agonist CP55,940, while reduces orthosteric inverse agonist SR141716A, CB1 binding. ZCZ011